Filing Details
- Accession Number:
- 0001209191-21-046028
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-07-08 18:15:57
- Reporting Period:
- 2021-07-06
- Accepted Time:
- 2021-07-08 18:15:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1576885 | Acumen Pharmaceuticals Inc. | ABOS | Biological Products, (No Disgnostic Substances) (2836) | 364108129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1804350 | D. Robert Hardie | C/O Acumen Pharmaceuticals, Inc. 427 Park Street Charlottesville VA 22902 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-07-06 | 2,950,484 | $0.00 | 3,040,193 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-07-06 | 312,500 | $16.00 | 3,352,693 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-07-06 | 657,985 | $0.00 | 657,985 | No | 4 | C | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2021-07-06 | 1,634,515 | $0.00 | 1,634,515 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2021-07-06 | 1,315,969 | $0.00 | 1,315,969 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2021-07-06 | 657,985 | $0.00 | 657,985 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "PreferredStock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering ofthe Issuer's common stock. The shares had no expiration date.
- The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
- The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, themanager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Billionaire Hedge Funds
